Scientists Find New Path to Cure Hepatitis B

For 15 years, doctors watched something remarkable happen when hepatitis B patients stopped taking their medications. About a third of them didn't just relapse. They got cured.

Scientists couldn't explain why until now. A team at UC San Francisco finally cracked the mystery by identifying the immune cells that spot the virus and launch a successful attack.

The key players are CD4+ T cells, a type of immune cell that coordinates the body's defenses. When these cells detect hepatitis B proteins in the liver, they sound the alarm and mobilize other immune forces to clear the infection. Without them, the virus keeps winning.

"It's taken us many years to explain why some of our patients are able to beat hepatitis B," said Dr. Jody Baron, a UCSF professor and study co-author. "We think this could lead to much better treatments based on the liver's natural biology."

The discovery matters for hundreds of millions of people living with hepatitis B worldwide. Current vaccines and treatments can control the infection, but more than a million people still die each year from complications. Most catch the virus at birth from their mothers, and their young immune systems never learn to fight back effectively.

The UCSF team engineered mice to carry the hepatitis B virus, then gave them immune cell transplants to see what would happen. Adult mice with CD4+ cells quickly recognized the threat and cleared the infection. Young mice couldn't, explaining why childhood hepatitis B becomes chronic while adults often beat it naturally.

The researchers then studied blood samples from patients who had stopped their antiviral medications. In patients who eventually cleared the virus, CD4+ cells in the liver became more active as the infection tried to rebound. In patients who couldn't shake the infection, those cells stayed quiet.

The Ripple Effect

This finding challenges decades of scientific focus on a different type of immune cell. Researchers have long believed CD8+ "killer" T cells were the main virus fighters, but CD4+ cells appear to be the essential coordinators that make everything else work.

The breakthrough opens a clear path forward. If CD4+ cells are the key to clearance, new therapies could activate them as patients taper off their medications, giving the immune system the push it needs to finish the job.

Dr. Stewart Cooper, another study co-author, sees the potential. "When treatment stops in a structured way, about a third of patients can mount the right immune response and clear the virus," he said. Now scientists understand why, and that knowledge could extend that success to many more patients.

The research appears in Science Translational Medicine, bringing hope to a global health challenge that has persisted for generations.